Russia’s sovereign wealth fund Russian Direct Investment Fund and Hyderabad-based Virchow Biotech have announced an agreement to produce up to 200 million doses per year of Sputnik V.
The technology transfer is expected to be completed in the second quarter of 2021, followed by full-scale commercial production of Sputnik V.
Over the last week, RDIF has announced production contracts with three domestic manufacturers, which can potentially vaccinate more than 300 million people with Sputnik V in a year.
Besides Virchow Biotech’s 200 million doses, which will vaccinate 100 million people, Bangalore-based Stelis Biopharma will roll out 200 million doses, and Hyderabad-based Gland Pharma, 252 million doses for 126 million people. Last year, RDIF had tied up with another Hyderabad-based Hetero for over 100 million doses. A majority of the companies are manufacturers of finished formulations, excluding Gland, and will have to repurpose their facilities and capabilities for making vaccines.
An RDIF spokesperson said in total, a production capacity for over 700 million people has been secured in 10 countries